Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2146 to 2160 of 8975 results

  1. AI technologies to aid the scoring and interpretation of diagnostic sleep studies

    Awaiting development Reference number: GID-HTG10174 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  2. Technology for cancer case finding using primary care records

    Awaiting development Reference number: GID-HTG10176 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  3. ProKnow cloud-based system for radiotherapy data storage, communication and management

    Awaiting development Reference number: GID-HTG10178 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  4. Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies

    Awaiting development Reference number: GID-HTG10177 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  5. Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [ID6677]

    Awaiting development Reference number: GID-TA11827 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Luspatercept for treating anaemia caused by myelofibrosis [ID6697]

    Awaiting development Reference number: GID-TA11915 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Rusfertide for treating polycythaemia vera in people having phlebotomy [ID6709]

    Awaiting development Reference number: GID-TA11937 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Topical tapinarof for treating atopic dermatitis in people 2 years and over [ID6713]

    Awaiting development Reference number: GID-TA11952 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6708]

    Awaiting development Reference number: GID-TA11953 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Sigvotatug vedotin for Non-small-cell lung cancer [ID6718]

    Awaiting development Reference number: GID-TA11942 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720]

    Awaiting development Reference number: GID-TA11874 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Camlipixant for treating refractory or unexplained chronic cough [ID6722]

    Awaiting development Reference number: GID-TA11707 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]

    In development Reference number: GID-TA10573 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

    Awaiting development Reference number: GID-TA10723 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]

    Awaiting development Reference number: GID-TA10823 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development